EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
Copyright policy )EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, has achieved high clinical response rates in patients with non-small cell lung cancers (NSCLCs). However, over time, most tumors develop acquired resistance to EGFR-TKIs, which is associated with the secondary EGFR T790M resistance mutation in about half the cases. Currently there are no effective treatment options for patients with this resistance mutation. Here we identified two novel HLA-A*0201 (A2)-restricted T cell epitopes containing the mutated methionine residue of the EGFR T790M mutation, T790M-5 (MQLMPFGCLL) and T790M-7 (LIMQLMPFGCL), as potential targets for EGFR-TKI-resistant patients. When peripheral blood cells were repeatedly stimulated in vitro with these two peptides and assessed by antigen-specific IFN-γ secretion, T cell lines responsive to T790M-5 and T790M-7 were established in 5 of 6 (83%) and 3 of 6 (50%) healthy donors, respectively. Additionally, the T790M-5- and T790M-7-specific T cell lines displayed an MHC class I-restricted reactivity against NSCLC cell lines expressing both HLA-A2 and the T790M mutation. Interestingly, the NSCLC patients with antigen-specific T cell responses to these epitopes showed a significantly less frequency of EGFR-T790M mutation than those without them [1 of 7 (14%) vs 9 of 15 (60%); chi-squared test, p = 0.0449], indicating the negative correlation between the immune responses to the EGFR-T790M-derived epitopes and the presence of EGFR-T790M mutation in NSCLC patients. This finding could possibly be explained by the hypothesis that immune responses to the mutated neo-antigens derived from T790M might prevent the emergence of tumor cell variants with the T790M resistance mutation in NSCLC patients during EGFR-TKI treatment. Together, our results suggest that the identified T cell epitopes might provide a novel immunotherapeutic approach for prevention and/or treatment of EGFR-TKI resistance with the secondary EGFR T790M resistance mutation in NSCLC patients.
- Harvard University United States
- Boston College United States
- Dana-Farber Cancer Institute United States
- Boston University United States
- Sendai Kousei Hospital Japan
Male, Lung Neoplasms, High-affinity, Epitopes, T-Lymphocyte, Lymphocyte Activation, Erlotinib hydrochloride, Epitopes, Lung neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic agents, Leukocytes, Middle aged, Gene expression regulation, Point mutation, Q, R, Gefitinib, Middle Aged, ErbB Receptors, Gene Expression Regulation, Neoplastic, Therapeutic cancer vaccines, epidermal growth factor, Medicine, Female, Immunotherapy, Lung cancer, Receptor, Research Article, T-lymphocyte, Science, Peptide complex, Molecular Sequence Data, Protein kinase inhibitors, mononuclear, 610, Antineoplastic Agents, Multidisciplinary sciences, Amino acid sequence, Erlotinib Hydrochloride, Growth-factor receptor, Molecular sequence data, HLA-A2 Antigen, Humans, Amino Acid Sequence, Lymphocyte activation, Aged, Tyrosine kinase inhibitors, Carcinoma, HLA-A2 antigen, neoplastic, non-small-cell lung, Drug Resistance, Neoplasm, Drug resistance, Mutation, Quinazolines, Clinical response, Leukocytes, Mononuclear, Acquired resistance, Science & technology, neoplasm
Male, Lung Neoplasms, High-affinity, Epitopes, T-Lymphocyte, Lymphocyte Activation, Erlotinib hydrochloride, Epitopes, Lung neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic agents, Leukocytes, Middle aged, Gene expression regulation, Point mutation, Q, R, Gefitinib, Middle Aged, ErbB Receptors, Gene Expression Regulation, Neoplastic, Therapeutic cancer vaccines, epidermal growth factor, Medicine, Female, Immunotherapy, Lung cancer, Receptor, Research Article, T-lymphocyte, Science, Peptide complex, Molecular Sequence Data, Protein kinase inhibitors, mononuclear, 610, Antineoplastic Agents, Multidisciplinary sciences, Amino acid sequence, Erlotinib Hydrochloride, Growth-factor receptor, Molecular sequence data, HLA-A2 Antigen, Humans, Amino Acid Sequence, Lymphocyte activation, Aged, Tyrosine kinase inhibitors, Carcinoma, HLA-A2 antigen, neoplastic, non-small-cell lung, Drug Resistance, Neoplasm, Drug resistance, Mutation, Quinazolines, Clinical response, Leukocytes, Mononuclear, Acquired resistance, Science & technology, neoplasm
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).17 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!